CAR-T Meeting 2022 | Updates on the use of narsoplimab in the treatment of TA-TMA
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, shares some updates on the use of narsoplimab, a lectin pathway inhibitor, which has shown to be effective in the treatment of transplant-associated thrombotic microangiopathy (TA-TMA). Dr Gavriilaki mentions the promising results obtained from narsoplimab so far, as well as other ongoing clinical trials which are investigating the use of complement inhibitors such as ravulizumab and pegcetacoplan. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi.
Dr Gavriilaki has received research support from Jazz Pharmaceuticals.
